PMID- 36868026
OWN - NLM
STAT- MEDLINE
DCOM- 20230331
LR  - 20230331
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 228
DP  - 2023 May 10
TI  - In-syringe dispersive solid phase filter extraction cleanup followed by liquid 
      chromatography-triple quadrupole mass spectrometry for fast determination of 
      colchicine in plasma/urine.
PG  - 115317
LID - S0731-7085(23)00086-9 [pii]
LID - 10.1016/j.jpba.2023.115317 [doi]
AB  - As an effective treatment for acute gouty arthritis and cardiovascular disease, 
      colchicine is also a toxic alkaloid and may cause poisoning or even death in 
      overdose. The study of colchicine elimination and the diagnosis of poisoning 
      etiology need the rapid and accurate quantitative analysis method in biological 
      matrix. An analytical method was developed for colchicine in plasma and urine by 
      in-syringe dispersive solid phase extraction (DSPE) followed by liquid 
      chromatography-triple quadrupole mass spectrometry (LC-MS/MS). Sample extraction 
      and protein precipitation were proceeded with acetonitrile. The extract was 
      cleaned by in-syringe DSPE. An XBridge BEH C(18) column（100 mm x 2.1 mm, 
      2.5 microm）was used to separate colchicine by gradient elution with mobile phase of 
      0.01% (v/v) ammonia-methanol. The amount and filling sequence of magnesium 
      sulfate (MgSO(4)) and primary secondary amine (PSA) suitable for in-syringe DSPE 
      were studied. Scopolamine was screened as the quantitative internal standard (IS) 
      for colchicine analysis according to the consistency of recovery rate, 
      chromatographic retention time and matrix effects. The limits of detection for 
      colchicine in plasma and urine were both 0.06 ng mL(-1) and the limits of 
      quantitation were both 0.2 ng mL(-1). The linear range was 0.04 - 20 ng mL(-1) 
      (Equivalent to 0.2-100 ng mL(-1) in plasma or urine) with a correlation 
      coefficient r > 0.999. By IS calibration, the average recoveries at three spiking 
      levels in plasma and urine were 95.3-102.68% and 93.9-94.8% with the relative 
      standard deviations (RSDs) of 2.9-5.7% and 2.3-3.4%, respectively. The matrix 
      effects, stability, dilution effects and carryover for determination of 
      colchicine in plasma and urine were also evaluated. The elimination of colchicine 
      within 72-384 h post-ingestion was studied for a poisoning patient with the doses 
      of 1 mg d(-1) for 39 days and then 3 mg d(-1) for 15 days).
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Qian, Ming-Rong
AU  - Qian MR
AD  - key Laboratory of Pollution Exposure and Health Intervention of Zhejiang 
      Province, Interdisciplinary Research Academy, Zhejiang Shuren University, 
      Hangzhou 310015, China.
FAU - Chen, Zhi-Min
AU  - Chen ZM
AD  - Lishui Bluetown Agricultural Testing Technology Co., Ltd., Lishui 323000, China.
FAU - Tao, Xue-Xin
AU  - Tao XX
AD  - key Laboratory of Pollution Exposure and Health Intervention of Zhejiang 
      Province, Interdisciplinary Research Academy, Zhejiang Shuren University, 
      Hangzhou 310015, China.
FAU - Yao, Feng
AU  - Yao F
AD  - Department of Emergency Medicine, the First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou 310003, China.
FAU - Xu, Xiao-Min
AU  - Xu XM
AD  - Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, 
      China. Electronic address: chemxuxm@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230227
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Humans
MH  - Chromatography, Liquid/methods
MH  - *Colchicine
MH  - *Tandem Mass Spectrometry/methods
MH  - Syringes
MH  - Solid Phase Extraction
MH  - Chromatography, High Pressure Liquid/methods
OTO - NOTNLM
OT  - Colchicine
OT  - Drug elimination
OT  - In-syringe dispersive solid phase extraction
OT  - Intoxication
OT  - Liquid chromatography
OT  - Triple quadrupole mass spectrometry
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper. Declaration of interest We declare 
      that we have no financial and personal relationships with other people or 
      organizations that can inappropriately influence our work.
EDAT- 2023/03/04 06:00
MHDA- 2023/03/31 06:42
CRDT- 2023/03/03 18:12
PHST- 2023/01/11 00:00 [received]
PHST- 2023/02/17 00:00 [revised]
PHST- 2023/02/23 00:00 [accepted]
PHST- 2023/03/31 06:42 [medline]
PHST- 2023/03/04 06:00 [pubmed]
PHST- 2023/03/03 18:12 [entrez]
AID - S0731-7085(23)00086-9 [pii]
AID - 10.1016/j.jpba.2023.115317 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2023 May 10;228:115317. doi: 10.1016/j.jpba.2023.115317. 
      Epub 2023 Feb 27.